In HLA-A24-positive patients with advanced HNSCC, a phase II clinical study investigated a vaccine based on short peptides derived from germline antigens, lymphocyte antigen 6 complex locus K (LY6K), cell division cycle associated gene 1 (CDCA1), and insulin-like growth factor-II mRNA-binding protein 3 (IMP3). Here, LY6K is linked to head and neck squamous cell carcinoma.